RESEARCH PAPER
The prevalence of HTLV-1 co-infection among people living with HIV in a tertiary care hospital in Tehran: a cross-sectional study
 
More details
Hide details
1
School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
 
2
Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences (TUMS), Tehran, Iran
 
3
Department of Health Information Technology, Khalkhal University of Medical Sciences, Khalkhal, Iran
 
4
Department of Infectious Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
 
5
Iranian Research Center for HIV/ AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran
 
6
Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
 
 
Submission date: 2021-11-13
 
 
Final revision date: 2022-04-05
 
 
Acceptance date: 2022-04-06
 
 
Online publication date: 2024-05-21
 
 
Corresponding author
SeyedAhmad SeyedAlinaghi   

Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High Risk Behaviors, Tehran University of Medical Sciences
 
 
HIV & AIDS Review 2024;23(2):136-140
 
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Human immunodeficiency virus (HIV) and human T cell leukemia/lymphoma virus type 1 (HTLV-1) share similar routes of transmission and both target T cells. HTLV-1 may negatively affect the course of disease in people living with HIV, but previous evidence is conflicting. Therefore, we aimed to investigate the prevalence of HIV/HTLV-1 co-infection, routes of transmission, and patients’ CD4+ counts.

Material and methods:
184 HIV-positive individuals were recruited for this cross-sectional study from the Counseling Center for Behavioral Diseases of Imam Khomeini Hospital in Tehran. Serum samples were analyzed using enzyme-linked immunosorbent assay (ELISA) for anti-HTLV-1.

Results:
The mean age of participants was 40.12 ± 11.6 years, and all cases were negative for HTLV-1 infection. Participants were diagnosed on average about 78 months (6 years) ago, and the mean CD4+ count of the participants was 669.22 cells/µl (SD = 284.2). Using ELISA screening, none of the participants from Tehran in various age groups showed concurrent HTLV-1 infection (0 percent).

Conclusions:
Co-infection with HTLV-1 is negligible in HIV-infected patients in Tehran, Iran. Our data also showed that the most common route of HIV transmission among our study subjects was hetero­sexual contact (56.4%).

 
REFERENCES (35)
1.
Shahmohamadi E, SeyedAlinaghi S, Karimi A, Behnezhad F, Mehraeen E, Dadras O. HIV/HTLV-1 co-infection: a systematic review of current evidence. HIV AIDS Rev 2021; 20: 158-165.
 
2.
Beilke MA, Theall KP, O’Brien M, Clayton JL, Benjamin SM, Winsor EL, et al. Clinical outcomes and disease progression among patients coinfected with HIV and human T lymphotropic virus types 1 and 2. Clin Infect Dis 2004; 39: 256-263.
 
3.
Brites C, Sampalo J, Oliveira A. HIV/human T-cell lymphotropic virus coinfection revisited: impact on AIDS progression. AIDS Rev 2009; 11: 8-16.
 
4.
Jahagirdar D, Walters MK, Novotney A, Brewer ED, Frank TD, Carter A, et al. Global, regional, and national sex-specific burden and control of the HIV epidemic, 1990-2019, for 204 countries and territories: the Global Burden of Diseases Study 2019. Lancet HIV 2021; 8: e633-e651. DOI: 10.1016/S2352-3018(21)00152-1.
 
5.
Rosadas C, Menezes MLB, Galvão-Castro B, Assone T, Miranda AE, Aragón MG, et al. Blocking HTLV-1/2 silent transmission in Brazil: current public health policies and proposal for additional strategies. PLoS Negl Trop Dis 2021; 15: e0009717. DOI: 10.1371/journal.pntd.0009717.
 
6.
Brites C, Goyanna F, França LG, Pedroso C, Netto EM, Adriano S, et al. Coinfection by HTLV-I/II is associated with an increased risk of strongyloidiasis and delay in starting antiretroviral therapy for AIDS patients. Braz J Infect Dis 2011; 15: 6-11.
 
7.
Ribeiro ML, Gonçales JP, Morais VMS, Moura L, Coêlho M. HTLV 1/2 Prevalence and risk factors in individuals with HIV/AIDS in Pernambuco, Brazil. Rev Soc Brasileira Med Trop 2019; 52: e20180244. DOI: 10.1590/0037-8682-0244-2018.
 
8.
Richey JD, Chen BJ, Deng AC. Indolent, waxing and waning cutaneous presentation of HTLV-1-associated adult T-cell leukemia/lymphoma in an HIV-1-positive patient. J Cutaneous Pathol 2018; 45: 171-175.
 
9.
Assone T, Kanashiro TM, Baldassin MPM, Paiva A, Haziot ME, Smid J, et al. In vitro basal T-cell proliferation among asymptomatic human T cell leukemia virus type 1 patients co-infected with hepatitis C and/or human immunodeficiency virus type 1. Braz J Infect Dis 2018; 22: 106-112.
 
10.
de Oliveira EH, Oliveira-Filho AB, Souza LA, da Silva LV, Ishak MO, Ishak R, et al. Human T-cell lymphotropic virus in patients infected with HIV-1: molecular epidemiology and risk factors for transmission in Piaui, Northeastern Brazil. Curr HIV Res 2012; 10: 700-707.
 
11.
Bhatt NB, Gudo ES, Semá C, Bila D, Di Mattei P, Augusto O, et al. Loss of correlation between HIV viral load and CD4+ T-cell counts in HIV/HTLV-1 co-infection in treatment naive Mozambican patients. Int J STD AIDS 2009; 20: 863-868.
 
12.
Yazdani R, Dadmanesh M, Ghorban K. First report of the prevalence of human T-lymphotropic virus type 1 (HTLV-1) for hemodialysis patients in Tehran. Arch Clin Infect Dis 2018; 13. DOI: 10.5812/archcid.65512.
 
13.
Isache C, Sands M, Guzman N, Figueroa D. HTLV-1 and HIV-1 co-infection: a case report and review of the literature. IDCases 2016; 4: 53-55.
 
14.
Ramezani A, Aghakhani A, Banifazl M, Boland-Ghamat Z, Foroughi M, Gachkar L, et al. Frequency of human T-Cell lymphotropic virus (HTLV) type 1 and 2 infection in HIV infected patients. Iranian J Pathol 2012; 7: 9-13.
 
15.
Alavi SM, Etemadi A. HIV/HBV, HIV/HCV and HIV/HTLV-1 co-infection among injecting drug user patients hospitalized at the infectious disease ward of a training hospital in Iran. Pak J Med Sci 2007; 23: 510-513.
 
16.
Phillips I, Hyams K, Wignall F, Moran A, Gotuzzo E, Sanchez J, et al. HTLV-I coinfection in a HIV-1-infected Peruvian population. J Acquir Immune Defic Syndr 1991; 4: 301-302.
 
17.
Mehraeen E, Oliaei S, SeyedAlinaghi S, Karimi A, Mirzapour P, Afsahi AM, et al. COVID-19 in pediatrics: the current knowledge and practice. Infect Disord Drug Targets 2022; 22: e290921196908. DOI: 10.2174/1871526521666210929121705.
 
18.
Schechter M, Moulton LH, Harrison LH. HIV viral load and CD4+ lymphocyte counts in subjects coinfected with HTLV-I and HIV-1. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 15: 308-311.
 
19.
Sobesky M, Couppie P, Pradinaud R, Godard MC, Alvarez F, Benoît B, et al. Coinfection with HIV and HTLV-I infection and survival in AIDS stage. French Guiana Study. GECVIG (Clinical HIV Study Group in Guiana). Presse Med 2000; 29: 413-416.
 
20.
SeyedAlinaghi S, Karimi A, MohsseniPour M, Barzegary A, Mirghaderi SP, Fakhfouri A, et al. The clinical outcomes of COVID‐19 in HIV‐positive patients: a systematic review of current evidence. Immun Inflamm Dis 2021; 9: 1160-1185.
 
21.
Gudo ES, Bhatt NB, Bila DR, Abreu CM, Tanuri A, Savino W, et al. Co-infection by human immunodeficiency virus type 1 (HIV-1) and human T cell leukemia virus type 1 (HTLV-1): does immune activation lead to a faster progression to AIDS? BMC Infect Dis 2009; 9: 211. DOI: 10.1186/1471-2334-9-211.
 
22.
Oliaei S, SeyedAlinaghi S, Mehrtak M, Karimi A, Noori T, Mirzapour P, et al. The effects of hyperbaric oxygen therapy (HBOT) on coronavirus disease-2019 (COVID-19): a systematic review. Eur J Med Res 2021; 26: 96. DOI: 10.1186/s40001-021-00570-2.
 
23.
Bessinger R, Beilke M, Kissinger P, Jarrott C, Tabak OF. Retroviral coinfections at a New Orleans HIV outpatient clinic. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14: 67-71.
 
24.
Araujo A, Sheehy N, Takahashi H, Hall W. Concomitant infections with human immunodeficiency virus type 1 and human T-lymphotropic virus types 1 and 2. In: Brogden KA, Guthmiller JM (eds.). Polymicrobial Diseases. Washington (DC): ASM Press; 2002.
 
25.
Mansouri Torshizi M, Khalighi AR, Fadavi Islam M, Aram R, Sabouri E, Khalilifar H, et al. Effect of human T-cell lymphotrophic virus type 1 (HTLV-1) in seropositive infertile women on intracytoplasmic sperm injection (ICSI) outcome. Iran J Reprod Med 2014; 12: 15-18.
 
26.
Kassa GM. Mother-to-child transmission of HIV infection and its associated factors in Ethiopia: a systematic review and meta-analysis. BMC Infect Dis 2018; 18: 216. DOI: 10.1186/s12879-018-3126-5.
 
27.
Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol 2012; 3: 388. DOI: 10.3389/fmicb.2012.00388.
 
28.
de Souza Lopes R, Serejo Pereira MV, Macedo da Silva R, de Luna Sales JB, Lima Gardunho DC, Cortinhas Monteiro J, et al. Molecular epidemiology of HIV-1 and HTLV-1/2 among female sex workers in four cities in the state of Para, Northern Brazil. Front Microbiol 2020; 11: 602664. DOI: 10.3389/fmicb.2020.602664.
 
29.
Moriuchi H, Moriuchi M. In vitro induction of HIV-1 replication in resting CD4(+) T cells derived from individuals with undetectable plasma viremia upon stimulation with human T-cell leukemia virus type I. Virology 2000; 278: 514-519.
 
30.
Beilke MA, Japa S, Vinson DG. HTLV-I and HTLV-II virus expression increase with HIV-1 coinfection. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17: 391-397.
 
31.
Böhnlein E, Siekevitz M, Ballard DW, Lowenthal JW, Rimsky L, Bogérd H, et al. Stimulation of the human immunodeficiency virus type 1 enhancer by the human T-cell leukemia virus type I tax gene product involves the action of inducible cellular proteins. J Virol 1989; 63: 1578-1586.
 
32.
Brites C, Sampalo J, Oliveira A. HIV/human T-cell lymphotropic virus coinfection revisited: impact on AIDS progression. AIDS Rev 2008; 11: 8-16.
 
33.
Casoli C, Pilotti E, Bertazzoni U. Molecular and cellular interactions of HIV-1/HTLV coinfection and impact on AIDS progression. AIDS Rev 2007; 9: 140-149.
 
34.
Moriuchi H, Moriuchi M, Fauci AS. Factors secreted by human T lymphotropic virus type I (HTLV-I)-infected cells can enhance or inhibit replication of HIV-1 in HTLV-I-uninfected cells: implications for in vivo coinfection with HTLV-I and HIV-1. J Exp Med 1998; 187: 1689-1697.
 
35.
Leung K, Nabel GJ. HTLV-1 transactivator induces interleukin-2 receptor expression through an NF-κB-like factor. Nature 1988; 333: 776-778.
 
eISSN:1732-2707
ISSN:1730-1270
Journals System - logo
Scroll to top